soul trial oral semaglutide cardiovascular outcomes nejm 2025 results 2024 ๐ฅSoul study group recently shared the Oral semaglutide reduces heart risks
Description
There are several conditions which can significantly
Not intended as a meal replacement or sole weight loss method
Suggesting GLP-1 receptor agonists may promote substantial weight loss through improved perceived regulation of eating behavior.
Expert guidance, dosing, application, and safety.
Over time, researchers discovered that the appetite-suppressing and weight-loss effects of GLP-1 receptor agonists had broader applications, including the treatment of obesity and obesity-related conditions such as OSA.These medications are typically synthesized using recombinant DNA technology
